OBJECTIVE: Acromegaly is a rare disease. Medical management with somatostatin analogs and the growth hormone receptor antagonist pegvisomant can normalize insulin-like growth factor-1 (IGF1) levels after failed surgery and decrease mortality and comorbidities. We present a case report of a patient with acromegaly on chronic hemodialysis resistant to first-generation, long-acting somatostatin analogs with remarkable response to pasireotide long-acting release (PAS-LAR). METHODS: A 66-year-old woman with acromegaly and chronic renal failure on hemodialysis resistant to lanreo-tide autogel (at 120 mg) was treated successfully with PAS-LAR. RESULTS: Acromegaly was diagnosed in 1996 and transsphenoidal resection of macroadenoma was performed with normalization of IGF1 levels. Nine years later, recurrence of the tumor led to a second operation. Lanreotide autogel was initiated due to persistently high levels of IGF1, but the patient was resistant to treatment. A positive response was observed with pegvisomant. However, the patient was nonadherent and treatment was discontinued. PAS-LAR was initiated and normalization of IGF1 and growth hormone was achieved. CONCLUSION: This is the first case report of a patient with acromegaly on chronic hemodialysis who was resistant to first-generation, long-acting somatostatin analogs and successfully treated with PAS-LAR.
OBJECTIVE: Acromegaly is a rare disease. Medical management with somatostatin analogs and the growth hormone receptor antagonist pegvisomant can normalize insulin-like growth factor-1 (IGF1) levels after failed surgery and decrease mortality and comorbidities. We present a case report of a patient with acromegaly on chronic hemodialysis resistant to first-generation, long-acting somatostatin analogs with remarkable response to pasireotide long-acting release (PAS-LAR). METHODS: A 66-year-old woman with acromegaly and chronic renal failure on hemodialysis resistant to lanreo-tide autogel (at 120 mg) was treated successfully with PAS-LAR. RESULTS: Acromegaly was diagnosed in 1996 and transsphenoidal resection of macroadenoma was performed with normalization of IGF1 levels. Nine years later, recurrence of the tumor led to a second operation. Lanreotide autogel was initiated due to persistently high levels of IGF1, but the patient was resistant to treatment. A positive response was observed with pegvisomant. However, the patient was nonadherent and treatment was discontinued. PAS-LAR was initiated and normalization of IGF1 and growth hormone was achieved. CONCLUSION: This is the first case report of a patient with acromegaly on chronic hemodialysis who was resistant to first-generation, long-acting somatostatin analogs and successfully treated with PAS-LAR.
Authors: Andrea Giustina; Philippe Chanson; David Kleinberg; Marcello D Bronstein; David R Clemmons; Anne Klibanski; Aart J van der Lely; Christian J Strasburger; Steven W Lamberts; Ken K Y Ho; Felipe F Casanueva; Shlomo Melmed Journal: Nat Rev Endocrinol Date: 2014-02-25 Impact factor: 43.330
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Anand K Annamalai; Alison Webb; Narayanan Kandasamy; Maysoon Elkhawad; Samantha Moir; Fakhar Khan; Kaisa Maki-Petaja; Emma L Gayton; Christopher H Strey; Samuel O'Toole; Shaumya Ariyaratnam; David J Halsall; Afzal N Chaudhry; Laurence Berman; Daniel J Scoffings; Nagui M Antoun; David P Dutka; Ian B Wilkinson; John M Shneerson; John D Pickard; Helen L Simpson; Mark Gurnell Journal: J Clin Endocrinol Metab Date: 2013-02-07 Impact factor: 5.958
Authors: Ammar Muhammad; Aart J van der Lely; Patric J D Delhanty; Alof H G Dallenga; Iain K Haitsma; Joseph A M J L Janssen; Sebastian J C M M Neggers Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958
Authors: Ursula Plöckinger; Susann Albrecht; Christian Mawrin; Wolfgang Saeger; Michael Buchfelder; Stephan Petersenn; Stefan Schulz Journal: J Clin Endocrinol Metab Date: 2008-01-15 Impact factor: 5.958
Authors: A Colao; M D Bronstein; P Freda; F Gu; C-C Shen; M Gadelha; M Fleseriu; A J van der Lely; A J Farrall; K Hermosillo Reséndiz; M Ruffin; Y Chen; M Sheppard Journal: J Clin Endocrinol Metab Date: 2014-01-13 Impact factor: 5.958